New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE

J Antibiot (Tokyo). 2019 Jul;72(7):524-534. doi: 10.1038/s41429-019-0164-1. Epub 2019 Mar 15.

Abstract

Ten analogues of a teicoplanin pseudoaglycon derivative have been synthesized with the aim of optimizing the in vitro activity of the compound against VanA type vancomycin resistant enterococci (VRE) isolated from hospitalized patients. Teicoplanin, vancomycin, and oritavancin were used as reference antibiotics for the antibacterial evaluations. One of the new derivatives exhibited far superior activity than the original compound. The in vitro MICs measured were comparable to that of oritavancin against the investigated VRE strains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cross Infection / microbiology
  • Drug Resistance, Bacterial
  • Gram-Positive Bacteria / drug effects
  • Lipoglycopeptides / pharmacology*
  • Microbial Sensitivity Tests
  • Teicoplanin / analogs & derivatives
  • Teicoplanin / chemical synthesis*
  • Teicoplanin / pharmacology*
  • Vancomycin-Resistant Enterococci / drug effects*

Substances

  • Anti-Bacterial Agents
  • Lipoglycopeptides
  • Teicoplanin
  • oritavancin